Billings Clinic
Especially For:

Clinical Trials

Title   Prostate Cancer (RTOG 0924): Androgen Deprivation and High dose Radiation Therapy With or Without Whole Pelvic Radiation
Description   A Phase III Randomized Trial of Androgen Deprivation Therapy and High Dose Radiation Therapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer.
IRB Number   RTOG 0924
Category   Prostate
Inclusion/Notes   Risk determined by the following combinations, must meet one of the three following combinations --
* Gleason 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml; * Gleason 6 + T2c-T4 or > 50% (positive) biopsies + PSA < 50 ng/ml;
* Gleason 6 + T1c-T2b (palpation) + PSA > 20 ng/ml.
Clinically negative lymph nodes as established by imaging w/in 90 days prior to registraiton.
No evidence of bone metastasis on bone scan w/in 120 day of registration.
Zubrod Performance Status = 0-1
Exclusion Criteria Includes (not a complete list): ~Prior invasive malignancy unless disease free for minimum 3 yrs; ~previous prostate surgery, pelvic/prostate radiation or hormone therapy; ~Prior finasteride, dutasteride or dutasteride/tamsulosin use within 30 - 90 days; ~previous or concurrent chemo for prostate cancer; ~No severe, active co-morbidities as defined per protocol
Status   Active/Open
Start Date   10/15/2012
Principal Investigator (PI)   John Schallenkamp, MD
Physician Profile   Radiatio Oncologist
Contact Name   Susan Dillon, RN
Contact Email   sdillon1@billingsclinic.org
Phone   (406) 435-7443
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.